Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02291029 · ClinicalTrials.gov registry record · Phase 2
Safety, Pharmacokinetics and Preliminary Efficacy Study of CFZ533 in Patients With Primary Sjögren's Syndrome
A Phase 2 study, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 69
- Enrollment target
NCT02291029 is a Phase 2 study that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 69 participants.
The verdict
NCT02291029, a Phase 2 study, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 69 participants
- Enrollment target
Study Summary
This study did evaluate the safety,tolerability and preliminary therapeutic efficacy of multiple doses of intravenous infusion of CFZ533 monoclonal antibody in patients with primary Sjögren's syndrome(pSS)
Interventions
- DRUG CFZ533 active - Cohort 1
- DRUG CFZ533 placebo- Cohort 1
- DRUG CFZ533 active - Cohort 2
- DRUG CFZ533 placebo - Cohort 2
- DRUG CFZ533 active -Cohort 3
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 69 participants |
| Start Date | 2014-10-22 |
| Est. Completion | 2018-06-29 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02291029
The ClinicalTrials.gov registry entry for NCT02291029 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 69 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which CFZ533 active - Cohort 1 is the first listed.
NCT02291029 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02291029 about?
NCT02291029 is a clinical study titled "Safety, Pharmacokinetics and Preliminary Efficacy Study of CFZ533 in Patients With Primary Sjögren's Syndrome". This study did evaluate the safety,tolerability and preliminary therapeutic efficacy of multiple doses of intravenous infusion of CFZ533 monoclonal antibody in patients with primary Sjögren's syndrome(pSS)
What is the current status of trial NCT02291029?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 69 participants. The study started on 2014-10-22. Estimated completion is 2018-06-29.
What interventions are being tested in trial NCT02291029?
The interventions under investigation include: CFZ533 active - Cohort 1 (DRUG), CFZ533 placebo- Cohort 1 (DRUG), CFZ533 active - Cohort 2 (DRUG), CFZ533 placebo - Cohort 2 (DRUG), CFZ533 active -Cohort 3 (DRUG).
Who is sponsoring clinical trial NCT02291029?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.